(NASDAQ: VNDA) Vanda Pharmaceuticals's forecast annual revenue growth rate of 27.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.9%, and while it is forecast to beat the US market's average forecast revenue growth rate of 16.13%.
Vanda Pharmaceuticals's revenue in 2026 is $217,782,000.On average, 7 Wall Street analysts forecast VNDA's revenue for 2026 to be $16,121,742,817, with the lowest VNDA revenue forecast at $15,305,703,240, and the highest VNDA revenue forecast at $16,859,004,807. On average, 7 Wall Street analysts forecast VNDA's revenue for 2027 to be $21,850,857,808, with the lowest VNDA revenue forecast at $19,919,303,557, and the highest VNDA revenue forecast at $23,804,662,218.
In 2028, VNDA is forecast to generate $26,095,225,774 in revenue, with the lowest revenue forecast at $23,808,871,707 and the highest revenue forecast at $28,856,049,426.